Evidence Summaries

A systematic review ¹ including 4 double-blind RCTs with a total of 1,465 subjects was abstracted in DARE. The patients were on a maintenance dose of 400 mg/day (low-dose treatment) for at least 12 months. A higher likelihood of experiencing adverse effects as a result of low-dose amiodarone was found: thyroid OR 4.2 (95% CI 2.0 to 8.7), neurologic OR 2.0 (1.1 to 3.7), skin OR 2.5 (1.1 to 6.2), ocular OR 3.4 (1.2 to 9.6), bradycardic OR 2.2 (1.1 to 4.3). The odds of discontinuing the drug in the amiodarone group were approximately 1.5 times that of the placebo group (OR 1.52, 95% CI 1.2 to 1.9).

According to another review ² abstracted in DARE, amiodarone appears to be associated with a low incidence of proarrhythmic events with torsade de pointes developing in less than 1% of cases.

The following decision support rules contain links to this evidence summary:

• Follow-up of patients who are on amiodaronehttp://www.ebmeds.org/ebmeds/ebmeds_home.asp...

References

1. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997 Sep;30(3):791-8.  [PMID:9283542]

2. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994 Oct 1;121(7):529-35.  [PMID:8067651]